BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
1/2/2024 9:08:47 AM | Browse: 442 | Download: 1783
Publication Name World Journal of Clinical Cases
Manuscript ID 88638
Country China
Received
2023-11-10 04:12
Peer-Review Started
2023-11-10 04:12
First Decision by Editorial Office Director
2023-11-22 01:09
Return for Revision
2023-11-22 01:09
Revised
2023-12-05 11:10
Publication Fee Transferred
Editorial Processing by Scientific Editor
2023-12-18 02:38
Final Academic Decision by Editor-in-Chief
Publication Technical Verification by Editorial Office Director
2023-12-18 07:28
Articles in Press
2023-12-18 07:28
Edit the Manuscript by Language Editor
Typeset the Manuscript
2023-12-26 03:15
Publish the Manuscript Online
2024-01-02 09:08
ISSN 2307-8960 (online)
Open Access This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Copyright © The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website http://www.wjgnet.com
Category Urology & Nephrology
Manuscript Type Retrospective Study
Article Title Efficacy and safety of Nafamostat mesylate in patients with end-stage renal failure
Manuscript Source Unsolicited Manuscript
All Author List Kun Liu and Zhen-Hua Li
ORCID
Author(s) ORCID Number
Zhen-Hua Li http://orcid.org/0009-0005-1993-3403
Funding Agency and Grant Number
Corresponding Author Zhen-Hua Li, MM, Chief Doctor, Department of Critical Care Medicine, General Hospital of The Yangtze River Shipping, Wuhan Brain Hospital, No. 5 Huiji Road, Wuhan 430015, Hubei Province, China. zhenh0911@163.com
Key Words End-stage renal failure; Nafamostat mesylate; Effectiveness; Safety study; Chronic kidney diseases
Core Tip End-stage renal disease refers to the terminal stage of the progression of various chronic kidney diseases, such as chronic nephritis, nephrotic syndrome, and tubulointerstitial disease. We aimed to evaluate the efficacy and safety of Nafamostat mesylate in patients with end-stage renal failure. Treatment of patients showing end-stage renal failure with Nafamostat mesylate can significantly improve therapeutic efficacy and has high safety and clinical value.
Publish Date 2024-01-02 09:08
Citation Liu K, Li ZH. Efficacy and safety of Nafamostat mesylate in patients with end-stage renal failure. World J Clin Cases 2024; 12(1): 68-75
URL https://www.wjgnet.com/2307-8960/full/v12/i1/68.htm
DOI https://dx.doi.org/10.12998/wjcc.v12.i1.68
Full Article (PDF) WJCC-12-68-with-cover.pdf
Full Article (Word) WJCC-12-68.docx